Updates on the Management of Autoimmune Blistering Diseases

Joanna N. Hooten, MD; Russell P. Hall 3rd, MD; Adela R. Cardones, MD


Skin Therapy Letter. 2014;19(5) 

In This Article


The treatment of AIBD varies greatly, but usually consists of topical or systemic steroids or combination therapy with steroid sparing agents or immunomodulators.[97] For PV, BP and EBA, finding the optimal treatment can be very difficult and often requires several dose adjustments or trial of an alternative steroid-sparing agent before the disease is well-controlled. Supportive care is often necessary to reduce the risk of complications and improve quality of life. This often requires collaborative approaches to therapy with ophthalmology and/or otolaryngology, when severe mucous membrane disease is present. For PV, first-line therapy is systemic corticosteroids and first-line adjunctive therapy is usually azathioprine or MM. Rituximab has recently been gaining ground as a treatment for refractory cases. The treatment algorithm for BP is similar. However, because patients with BP tend to have more comorbidities, early transition to combination or steroid-sparing therapy may be necessary.